慢性肝病已经逐渐成为严重的全球性健康问题。肝活体组织检查是目前评价肝脏病变的金标准，但其属于有创操作且会造成严重并发症；因此，亟需一种可用于诊断的经济快速的无创检测方法应用于临床。近十几年来，蛋白质糖基化已成为研究热点；血清蛋白聚糖结构的变化是肝脏损伤的指征这一理念也逐渐得到众多研究者们的认可。同时，高效的糖谱分析技术（基于DNA测序仪的荧光毛细管电泳技术，DSA-FACE）也为各种慢性肝病带来了具有较高灵敏度和特异度的诊断模型（GlycoHepatoTest），是肝病无创诊断的新策略。“,”Chronic liver disease has gradually become a serious health problem worldwide. Liver biopsy is the current gold standard to assess liver lesions; however, it is an invasive procedure that may cause severe complications. Therefore, there is an urgent need for an economical and rapid non-invasive detection method that can be used in clinic for diagnosis. In the past decade, protein glycosylation has become a research hotspot, and the concept of changes in serum proteoglycans structure has gradually been accepted by many researchers as an indication of liver injury. At the same time, N-linked glycans via DNA sequencing equipment-Fluorophore Assisted Carbohydrate Electrophoresis (DSA-FACE) has also brought high sensitivity and specificity diagnostic models (GlycoHepatoTest) for various chronic liver diseases, which is a new strategy for non-invasive diagnosis of liver diseases.